Sumitomo Dainippon Pharma Stock Price, News & Analysis
Company Description
Sumitomo Dainippon Pharma (OTC Link: SMDPY) is a publicly traded drug manufacturers - specialty & generic company in the Healthcare sector. The company has a market capitalization of $4.6B.
SMDPY stock has gained 93.3% over the past year. Shares last traded at $11.75.
This page provides a comprehensive overview of SMDPY stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Sumitomo Dainippon Pharma (SMDPY) stock last traded at $11.75. Over the past 12 months, the stock has gained 93.3%. At a market capitalization of $4.6B, SMDPY is classified as a mid-cap stock with approximately 397.3M shares outstanding.
Latest News
Sumitomo Dainippon Pharma has 1 recent news article. View all SMDPY news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Sumitomo Dainippon Pharma (SMDPY) currently stands at 20 shares, down 97.7% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 99.9%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Sumitomo Dainippon Pharma (SMDPY) currently stands at 1.4 days, up 43% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has decreased 71% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.
SMDPY Company Profile & Sector Positioning
Sumitomo Dainippon Pharma (SMDPY) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing SMDPY often look at related companies in the same sector, including Hikma Pharmaceuticals Plc (HKMPY), Hikma Pharma (HKMPF), Procaps Group Sa (PROCF), Almirall (LBTSF), and Almirall SA (ALMRY). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SMDPY's relative position within its industry.